Skip to main content

Table 1 The clinical, CT and pathological characteristics of MA

From: Adult metanephric adenoma presumed to be all benign? A clinical perspective

NO.

Sex/Age (years)

Tumor size (cm)

Unenhanced/enhanced attenuation(Hu)

Treatment modality

Pathology diagnosis

Recurrence or metastasis

1

F/48

2

37/61

NSS

MA

NO

2

F/65

3

30/87

RN

MA

NO

3

M/62

6.2

9/12

RN

MA

NO

4

M/45

4

21/42

RN

MA, PT

NO

5

F/33

2

20/25

NSS

MA

NO

6

F/64

4.5

30/46

RN

MA

NO

7

F/53

6.5

36/58

RN

MA, PT

NO

8

M/64

6

45/71

RN

MA

NO

9

F/38

5

46/107

RN

MA

NO

10

M/65

2.7

43/51

NSS

MA, AC

NO

11

F/50

9

20/58

RN

MA, CCC,

NO

12

M/50

4.3

25/53

RN

MA

NO

13

F/38

3.5

25/30

NSS

Malignant

NO

14

M/33

3.5

24/58

RN

MA

NO

15

F/47

4.7

33/76

RN

MA,OC

NO

16

M/43

4

26/64

RN

Malignant

M

17

M/51

3

28/34

RN

MA

NO

18

M/18

5.3

32/46

RN

MA, PT

NO

  1. F: female, M: male, RN: radical nephrectomy, NSS: nephron sparing surgery, MA: Metanephric adenomas, CCC:chromophobe cell carcinoma, OC: Oncocytic carcinoma, PT: Papillary tumor, AC: adenocarcinoma, M: metastasis.